Ironwood Pharmaceuticals, Inc. — 2021 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2021; it is not a standalone Q4 filing. Ironwood is a gastrointestinal-focused company whose revenue is primarily tied to LINZESS, commercialized in the U.S. through an equal-profit-and-loss collaboration with AbbVie. The company also reported early-stage programs IW-3300 and CNP-104.
Financial performance and position
| Metric | 2021 | 2020 |
|---|---|---|
| Total revenue | $413.8 million | $389.5 million |
| LINZESS U.S. collaboration revenue | $400.4 million | $368.6 million |
| Operating income | $232.3 million | $142.9 million |
| Income before taxes | $200.7 million | $108.9 million |
| Net income | $528.4 million | $106.2 million |
| Cash from operating activities | $261.9 million | $168.8 million |
| Cash and cash equivalents at year-end | $620.1 million | $362.6 million |
- Revenue rose 6%; U.S. LINZESS collaboration revenue increased 9%, mainly on higher prescription demand, partly offset by net price erosion.
- Operating margin was approximately 56% in 2021 versus 37% in 2020, calculated as reported operating income divided by revenue. No cost of revenues was reported for 2021.
- Net income included a $333.3 million non-cash tax benefit from releasing most of the valuation allowance on deferred tax assets. The benefit, rather than operating growth alone, accounts for much of the increase in reported net income.
- Year-end debt principal was $520.7 million; net carrying value was $454.2 million. Of the principal, $120.7 million of 2.25% convertible notes was due in June 2022. Cash substantially exceeded debt principal at year-end.
- Cash increased by $257.1 million during 2021. Investing activities used $0.3 million and financing activities used $4.6 million.
- Q4 2021 reported revenue of $117.1 million and net income of $41.4 million, compared with $116.7 million and $43.2 million, respectively, in Q4 2020.
Material changes versus the prior comparable period
- Operating income increased as LINZESS U.S. collaboration revenue grew and research and development and selling, general and administrative expenses declined. R&D expense fell 20% to $70.4 million; SG&A fell 21% to $111.1 million.
- API sales declined to $1.0 million from $8.0 million, principally reflecting the transition of China supply responsibilities to AstraZeneca.
- Cash from operations increased to $261.9 million from $168.8 million.
- Ironwood recognized a $19.5 million R&D expense related to its COUR agreement. The agreement provides an option to license CNP-104 in the U.S.; exercising it would require a further $35.0 million payment, with potential commercial milestones of up to $440.0 million and royalties.
- The company repurchased 2.4 million shares for $27.1 million during 2021. It had $122.9 million remaining under its $150.0 million authorization at year-end.
Outlook, commentary, and risks
- Management expects year-end cash and anticipated operating inflows to cover near- and long-term obligations, and said cash on hand was sufficient for projected operating needs for at least 12 months from issuance of the financial statements. No specific revenue or earnings guidance was provided.
- LINZESS remains the company’s principal revenue source, with U.S. collaboration revenue representing most of total revenue. Prescription demand, pricing and rebates, wholesaler purchasing patterns, and AbbVie-reported sales and costs can affect results.
- The company identified competition, reimbursement and drug-pricing pressure, generic entry, reliance on partners and third-party manufacturers, supply-chain disruption, patent protection, clinical and regulatory outcomes, and COVID-19 impacts as material risks. Known generic settlements permit licensed LINZESS generic entry as early as March 31, 2029, subject to FDA approval and specified conditions.
- IW-3300 entered Phase I in Q1 2022. COUR’s CNP-104 study was ongoing; Ironwood’s license option remained subject to review of study data. Neither program had established commercial prospects.
- Other unusual items included the non-cash deferred-tax benefit and the prior-period discontinuation of IW-3718; related restructuring expense was largely recorded in 2020. Management reported effective disclosure controls and internal control over financial reporting; the auditor issued unqualified opinions.
Important facts for investors to verify
- Whether LINZESS U.S. prescription growth continues and offsets net price erosion, rebates, and commercial costs.
- The cash repayment, conversion, or refinancing outcome for the $120.7 million 2022 notes and the terms and timing of remaining convertible debt.
- The sustainability of operating profitability and cash generation excluding the one-time, non-cash tax valuation-allowance release.
- Progress and results from IW-3300 and COUR’s CNP-104 study, and whether Ironwood exercises its CNP-104 option and incurs related future payments.
- Any changes in generic-litigation status, patent coverage, partner performance, product supply, or reimbursement access.
- Subsequent-event share repurchases: from January 1 to February 15, 2022, the company repurchased 4.5 million shares for $50.7 million at a weighted-average price of $11.27.